Abeona Therapeutics financials
$5.16−2.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $0.00 | $3.5M | $1.4M | $3.0M | $10.0M | $0.00 | $3.0M | $837.0K | $889.0K |
| Gross profit | $4.3M | $0.00 | $3.5M | $1.4M | $3.0M | $10.0M | $0.00 | $3.0M | $837.0K | $889.0K |
| Gross margin | 73.7% | — | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M | -$81.4M | -$77.1M | -$58.2M | -$27.8M | -$23.9M |
| Net income | $71.2M | -$63.7M | -$54.2M | -$43.5M | -$84.9M | -$84.2M | -$76.3M | -$56.7M | -$27.3M | -$21.9M |
| Net margin | 1223.1% | — | −1548.2% | −3074.8% | −2831.2% | −842.3% | — | −1890.3% | −3263.9% | −2460.4% |
| Diluted EPS | $1.01 | $-1.55 | $-2.53 | $-5.53 | $-21.57 | $-22.75 | $-37.75 | $-29.75 | $-16.50 | $-16.00 |
| EBITDA | -$86.9M | -$62.2M | -$44.8M | -$43.2M | -$52.9M | -$42.9M | -$69.3M | -$55.8M | -$27.1M | -$23.1M |
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M | -$35.0M | -$62.8M | -$39.1M | -$22.7M | -$10.4M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M | -$36.4M | -$69.1M | -$48.4M | -$23.5M | -$10.9M |
| Diluted shares | 66.1M | 41.0M | 21.4M | 7.9M | 3.9M | 3.7M | 2.0M | 1.9M | 1.7M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.4M | $23.4M | $14.5M | $14.2M | $32.9M | $12.6M |
| Short-term investments | $113.0M | $74.4M | $37.8M | $37.9M | $12.1M | $82.4M |
| Total debt | $20.0M | $19.0M | $4.6M | $0.00 | $0.00 | $1.8M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M | $151.2M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M | $48.6M |
| Shareholders' equity | $159.2M | $44.0M | $14.8M | $26.8M | $42.4M | $102.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology